Vaccines to Prevent Meningitis: Historical Perspectives and Future Directions
Open Access
- 7 April 2021
- journal article
- review article
- Published by MDPI AG in Microorganisms
- Vol. 9 (4) , 771
Abstract
Despite advances in the development and introduction of vaccines against the major bacterial causes of meningitis, the disease and its long-term after-effects remain a problem globally. The Global Roadmap to Defeat Meningitis by 2030 aims to accelerate progress through visionary and strategic goals that place a major emphasis on preventing meningitis via vaccination. Global vaccination against Haemophilus influenzae type B (Hib) is the most advanced, such that successful and low-cost combination vaccines incorporating Hib are broadly available. More affordable pneumococcal conjugate vaccines are becoming increasingly available, although countries ineligible for donor support still face access challenges and global serotype coverage is incomplete with existing licensed vaccines. Meningococcal disease control in Africa has progressed with the successful deployment of a low-cost serogroup A conjugate vaccine, but other serogroups still cause outbreaks in regions of the world where broadly protective and affordable vaccines have not been introduced into routine immunization programs. Progress has lagged for prevention of neonatal meningitis and although maternal vaccination against the leading cause, group B streptococcus (GBS), has progressed into clinical trials, no GBS vaccine has thus far reached Phase 3 evaluation. This article examines current and future efforts to control meningitis through vaccination.Keywords
Funding Information
- Bill and Melinda Gates Foundation (OPP1116594)
This publication has 75 references indexed in Scilit:
- Advance market commitment for pneumococcal vaccines: putting theory into practiceBulletin of the World Health Organization, 2011
- Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type b vaccine experiencePhilosophical Transactions of the Royal Society B: Biological Sciences, 2011
- Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in AfricansNew England Journal of Medicine, 2011
- Supporting new vaccine introduction decisions: Lessons learned from the Hib Initiative experienceVaccine, 2010
- The impact of vaccines on pneumonia: Key lessons from Haemophilus influenzae type b conjugate vaccinesVaccine, 2008
- Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trialThe Lancet, 2005
- Vaccines against bacterial meningitisBritish Medical Bulletin, 2004
- A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV InfectionNew England Journal of Medicine, 2003
- New tendencies and strategies in international immunisation: GAVI and The Vaccine FundVaccine, 2003
- Meningococcal meningitis in AfricaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1999